| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $50.0M | — |
| Cost of Revenue | $3.1M | — |
| R&D Expense | $33.4M | — |
| SG&A Expense | $124.7M | — |
| Operating Income | -$112.0M | — |
| Interest Expense | $1.4M | — |
| Pre-tax Income | -$110.6M | — |
| Income Tax | -$1.0M | — |
| Net Income | -$109.5M | — |
| EPS (Basic) | -$2.03 | — |
| EPS (Diluted) | -$2.03 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $229.3M | +25.8% |
| Accounts Receivable | $2.6M | — |
| Inventory | $3.4M | — |
| Current Assets | $320.1M | +11.9% |
| Total Assets | $335.4M | +13.8% |
| Current Liabilities | $57.4M | +119.6% |
| Long-term Debt | $172.2M | — |
| Total Liabilities | $338.1M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$81.6M | — |
| Capital Expenditures | $1.7M | — |
| Investing Cash Flow | $18.7M | — |
| Financing Cash Flow | $162.6M | — |
| Free Cash Flow | -$83.3M | — |
| +159.2% |
| Stockholders' Equity | -$2.7M | -101.6% |